High glucose and interleukin-1β downregulate interleukin-1 type I receptor (IL-1RI) in retinal endothelial cells by enhancing its degradation by a lysosome-dependent mechanism

Cytokine

Volumn 49, Issue 3, 2010, Pages 279-286

  Aveleira, Célia ^a   Castilho, Áurea ^a   Baptista, Filipa ^a   Simões, Núria ^a   Fernandes, Carolina ^a   Leal, Ermelindo ^a,b   Ambrósio, António Francisco ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Diabetic retinopathy; IL 1 ; IL 1RI; Protein degradation; Retinal endothelial cells

Indexed keywords

AMMONIUM CHLORIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CHLOROQUINE; GLUCOSE; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE I ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; LACTACYSTIN; MANNITOL; PROTEASOME INHIBITOR; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL NUCLEUS MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; INHIBITION KINETICS; INTRACELLULAR TRANSPORT; LONG TERM EXPOSURE; LYSOSOME; NONHUMAN; OSMOTIC STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN SYNTHESIS REGULATION; PROTEIN TRANSPORT; RAT; REACTION TIME; RECEPTOR DOWN REGULATION; RETINA CELL; TRANSPORT KINETICS;

ANIMALS; BLOOD-RETINAL BARRIER; CELL LINE; DIABETIC RETINOPATHY; DOWN-REGULATION; ENDOTHELIAL CELLS; ENZYME INHIBITORS; GLUCOSE; HUMANS; INTERLEUKIN-1BETA; LYSOSOMES; MANNITOL; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, TRANSGENIC; RECEPTORS, INTERLEUKIN-1 TYPE I; RETINA;

EID: 75449089500     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.11.014     Document Type: Article

References (48)

1. Cunha-Vaz J.G. Diabetic retinopathy: surrogate outcomes for drug development for diabetic retinopathy. Ophthalmologica 214 (2000) 377-380
2. Aiello L.P., Gardner T.W., King G.L., Blankenship G., Cavallerano J.D., Ferris III F.L., et al. Diabetic retinopathy. Diabetes Care 21 (1998) 143-156
3. Cunha-Vaz J.G. The blood-retinal barriers system. Basic concepts and clinical evaluation. Exp Eye Res 78 (2004) 715-721
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med 1993;329:977-86.
5. Miyamoto K., Khosrof S., Bursell S.E., Rohan R., Murata T., Clermont A.C., et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 96 (1999) 10836-10841
6. Leal E.C., Manivannan A., Hosoya K., Terasaki T., Cunha-Vaz J., Ambrosio A.F., et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 48 (2007) 5257-5265
7. Antonetti D.A., Barber A.J., Khin S., Lieth E., Tarbell J.M., and Gardner T.W. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn state retina research group. Diabetes 47 (1998) 1953-1959
8. Carmo A. Breakdown of the inner and outer blood retinal barrier in streptozotocin-induced diabetes. Exp Eye Res 67 (1998) 569-575
9. Joussen A.M., Murata T., Tsujikawa A., Kirchhof B., Bursell S.E., and Adamis A.P. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 158 (2001) 147-152
10. Abu el Asrar A.M., Maimone D., Morse P.H., Gregory S., and Reder A.T. Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol 114 (1992) 731-736
11. Yuuki T., Kanda T., Kimura Y., Kotajima N., Tamura J., Kobayashi I., et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications 15 (2001) 257-259
12. Demircan N., Safran B.G., Soylu M., Ozcan A.A., and Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye 20 (2006) 1366-1369
13. Joussen A.M., Huang S., Poulaki V., Camphausen K., Beecken W.D., Kirchhof B., et al. In vivo retinal gene expression in early diabetes. Invest Ophthalmol Vis Sci 42 (2001) 3047-3057
14. Carmo A., Cunha-Vaz J.G., Carvalho A.P., and Lopes M.C. L-arginine transport in retinas from streptozotocin diabetic rats: correlation with the level of IL-1 beta and NO synthase activity. Vision Res 39 (1999) 3817-3823
15. Gerhardinger C., Costa M.B., Coulombe M.C., Toth I., Hoehn T., and Grosu P. Expression of acute-phase response proteins in retinal Muller cells in diabetes. Invest Ophthalmol Vis Sci 46 (2005) 349-357
16. Kowluru R.A., and Odenbach S. Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. Invest Ophthalmol Vis Sci 45 (2004) 4161-4166
17. Krady J.K., Basu A., Allen C.M., Xu Y., LaNoue K.F., Gardner T.W., et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 54 (2005) 1559-1565
18. Joussen A.M., Poulaki V., Mitsiades N., Kirchhof B., Koizumi K., Dohmen S., et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. Faseb J 16 (2002) 438-440
19. Carmo A., Cunha-Vaz J.G., Carvalho A.P., and Lopes M.C. Effect of cyclosporin-A on the blood-retinal barrier permeability in streptozotocin-induced diabetes. Mediators Inflamm 9 (2000) 243-248
20. Bamforth S.D., Lightman S.L., and Greenwood J. Ultrastructural analysis of interleukin-1 beta-induced leukocyte recruitment to the rat retina. Invest Ophthalmol Vis Sci 38 (1997) 25-35
21. Rothwell N.J., and Luheshi G.N. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci 23 (2000) 618-625
22. Sparacio S.M., Zhang Y., Vilcek J., and Benveniste E.N. Cytokine regulation of interleukin-6 gene expression in astrocytes involves activation of an NF-kappa B-like nuclear protein. J Neuroimmunol 39 (1992) 231-242
23. Chung I.Y., and Benveniste E.N. Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. J Immunol 144 (1990) 2999-3007
24. Chai Z., Gatti S., Toniatti C., Poli V., and Bartfai T. Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice. J Exp Med 183 (1996) 311-316
25. Sims J.E., Gayle M.A., Slack J.L., Alderson M.R., Bird T.A., Giri J.G., et al. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci USA 90 (1993) 6155-6159
26. Cullinan E.B., Kwee L., Nunes P., Shuster D.J., Ju G., McIntyre K.W., et al. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol 161 (1998) 5614-5620
27. Dower S.K., Kronheim S.R., March C.J., Conlon P.J., Hopp T.P., Gillis S., et al. Detection and characterization of high affinity plasma membrane receptors for human interleukin 1. J Exp Med 162 (1985) 501-515
28. Mizel S.B., Kilian P.L., Lewis J.C., Paganelli K.A., and Chizzonite R.A. The interleukin 1 receptor. Dynamics of interleukin 1 binding and internalization in T cells and fibroblasts. J Immunol 138 (1987) 2906-2912
29. Boraschi D., Rambaldi A., Sica A., Ghiara P., Colotta F., Wang J.M., et al. Endothelial cells express the interleukin-1 receptor type I. Blood 78 (1991) 1262-1267
30. Thieme T.R., Hefeneider S.H., Wagner C.R., and Burger D.R. Recombinant murine and human IL 1 alpha bind to human endothelial cells with an equal affinity, but have an unequal ability to induce endothelial cell adherence of lymphocytes. J Immunol 139 (1987) 1173-1178
31. Konsman J.P., Vigues S., Mackerlova L., Bristow A., and Blomqvist A. Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J Comp Neurol 472 (2004) 113-129
32. Mantovani A., Bussolino F., and Introna M. Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol Today 18 (1997) 231-240
33. Pober J.S. Activation and injury of endothelial cells by cytokines. Pathol Biol (Paris) 46 (1998) 159-163
34. Hosoya K., Tomi M., Ohtsuki S., Takanaga H., Ueda M., Yanai N., et al. Conditionally immortalized retinal capillary endothelial cell lines (TR-iBRB) expressing differentiated endothelial cell functions derived from a transgenic rat. Exp Eye Res 72 (2001) 163-172
35. Levrand S., Pesse B., Feihl F., Waeber B., Pacher P., Rolli J., et al. Peroxynitrite is a potent inhibitor of NF-{kappa}B activation triggered by inflammatory stimuli in cardiac and endothelial cell lines. J Biol Chem 280 (2005) 34878-34887
36. Heguy A., Baldari C., Bush K., Nagele R., Newton R.C., Robb R.J., et al. Internalization and nuclear localization of interleukin 1 are not sufficient for function. Cell Growth Differ 2 (1991) 311-315
37. Qwarnstrom E.E., Page R.C., Gillis S., and Dower S.K. Binding, internalization, and intracellular localization of interleukin-1 beta in human diploid fibroblasts. J Biol Chem 263 (1988) 8261-8269
38. Kowluru R.A., and Odenbach S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. Br J Ophthalmol 88 (2004) 1343-1347
39. Rosette C., and Karin M. Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors. Science 274 (1996) 1194-1197
40. Ye K., Koch K.C., Clark B.D., and Dinarello C.A. Interleukin-1 down-regulates gene and surface expression of interleukin-1 receptor type I by destabilizing its mRNA whereas interleukin-2 increases its expression. Immunology 75 (1992) 427-434
41. McGee D.W., Vitkus S.J., and Lee P. The effect of cytokine stimulation on IL-1 receptor mRNA expression by intestinal epithelial cells. Cell Immunol 168 (1996) 276-280
42. Takii T., Hayashi H., Marunouchi T., and Onozaki K. Interleukin-1 down-regulates type I interleukin 1 receptor mRNA expression in a human fibroblast cell line TIG-1 in the absence of prostaglandin E2 synthesis. Lymphokine Cytokine Res 13 (1994) 213-219
43. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147
44. Sims J.E., and Dower S.K. Interleukin-1 receptors. Eur Cytokine Netw 5 (1994) 539-546
45. Rungger-Brandle E., Dosso A.A., and Leuenberger P.M. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci 41 (2000) 1971-1980
46. Zeng X.X., Ng Y.K., and Ling E.A. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci 17 (2000) 463-471
47. Curtis B.M., Widmer M.B., deRoos P., and Qwarnstrom E.E. IL-1 and its receptor are translocated to the nucleus. J Immunol 144 (1990) 1295-1303
48. Vincent J.A., and Mohr S. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 56 (2007) 224-230